Breast cancer remains the most common nonskin cancer among women and a leading cause of morbidity and mortality. Early detection through screening and advances in treatment have contributed to a 39% mortality reduction in the United States since 1990. The NCCN Guidelines for Breast Cancer Screening and Diagnosis recommend annual mammographic screening for average-risk women beginning at age 40 years. Mammographic screening and subsequent treatment reduces breast cancer mortality based on a wide range of studies. This article highlights NCCN's position on screening mammography and the screening controversy.
Recognizing that the purpose of breast cancer screening is to decrease breast cancer mortality and morbidity, NCCN continues to recommend annual screening mammography beginning at age 40 years for averagerisk women. Mammographic screening and subsequent treatment based on those results reduces breast cancer mortality based on a wide range of studies using various methodologies. [1] [2] [3] [4] Recent publicity emphasizing differences between various mammographic screening recommendations has masked fundamental areas of agreement among major organizations in the United States, all of which recommend routine screening mammography. Analysis by these key organizations, including the American Cancer Society (ACS) and US Preventive Services Task Force (USPSTF), have shown that the maximum mortality reduction and life years gained (LYG) benefit occurs when screening begins at age 40 years. 1 This article highlights NCCN's position on screening mammography for average-risk women, emphasizing important factors considered by NCCN, but is not intended as a comprehensive screening review or assessment of emerging supplemental screening technologies covered elsewhere. 5 NCCN believes that women electing to undergo screening mammography should be counseled regarding potential benefits, risks, and limitations, and shared decision-making is encouraged.
Breast cancer is a major worldwide health problem. In the United States, 12.5%, or 1 in 8 women, will develop breast cancer during their lifetime. In 2018, an estimated 266,120 cases of invasive breast cancer and 63,960 cases of in situ carcinoma will be diagnosed. 6 In contrast, during the same year, 112,350 women will be diagnosed with lung cancer, 26,240 with pancreatic cancer, and 13,240 with cervical cancer. 6 Breast cancer is the most common nonskin cancer impacting women: an estimated 40,920 women will die of the disease in 2018. 6 Since 1990, the mortality rate in the United States has decreased by a remarkable 39%, which has been attributed to advances in screening, treatment, and early detection. 6 An even greater 49% mortality decline is estimated when adjustments are made for existing background mortality trends. 7 Invasive breast cancer incidence in the United States has remained stable since the late 1980s. 2 In contrast, WHO data shows worldwide mortality and incidence rates increased (2.8% and 4% per year, respectively) from 2008 through 2012. 8 The progress made in the United States and other countries is lacking in much of the world.
Why do organizations differ on screening recommendations? In substantial measure, these reveal different subjective value judgements between the benefits (deaths averted or LYG) versus the risks (harms). These differences also reflect whether the perspective is individual or population-based. Screening recommendations differ primarily in terms of age of initiation and frequency of screening, and these differences have caused confusion among women and providers regarding appropriate use of mammography, which may contribute to its current underuse. There has been more consistency regarding the age at which to stop screening and the need to integrate overall patient health in screening decisions. Table 1 summarizes the guidelines by several major organizations. In 2016, in an attempt to harmonize the various recommendations, the American College of Obstetricians and Gynecologists (ACOG) held a consensus conference in Washington, DC, which included members from NCCN, American Academy of Family Physicians, ACS, American College of Physicians, American College of Radiology, American College of Surgeons, and USPSTF. The goal was to produce a screening document on which all organizations could agree. However, consensus could not be reached due to the differences regarding age of onset and frequency.
The NCCN Breast Cancer Screening and Diagnosis Panel subsequently convened in 2017 and affirmed that the primary purpose of screening is to decrease mortality and treatment-related morbidity. NCCN prioritized the benefits of screening over the known risks. In addition to mortality benefit, mammography can confer morbidity benefit, including fewer mastectomies, fewer axillary dissections, and more limited use of chemotherapy compared with nonscreened women.
9-12 NCCN recognizes individual women will weigh benefits and risks differently, but believes women should have the opportunity to exercise their personal decision in choosing an appropriate screening strategy that allows maximal benefit, and that this should be a covered service.
A major impediment to organizational consensus is the inability to quantitate the value of a death averted or LYG compared with a nonlethal risk, such as a recall, needle breast biopsy, or potential overdiagnosed cancer. Women have placed a high value on the benefits of mortality reduction compared with the risks. Schwartz et al 13 showed that 63% of women thought ≥500 false-positives per life saved was acceptable, and 62% "did not want to take falsepositive results into account when deciding about screening."
Interestingly, since publication of the controversial 2009 USPSTF guidelines, 88% of surveyed internists, family medicine physicians, and gynecologists recommend screening mammography for women aged 45 to 49 years and 81% for women aged 40 to 44 years.
14 These results show continued disconnect between certain organizational guidelines and practicing physicians' actions. USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.
c USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.
Evidence for Screening
There are 2 major lines of evidence to support screening mammography: historic randomized controlled trials (RCTs) that assessed efficacy, and more recent observational population-based studies that have estimated effectiveness. Computer models have also been used to compare various screening regimens because direct RCT comparative evidence is lacking, but these models are subject to input assumptions. Most RCT studies used older film-screen mammography, which has been replaced by more effective digital mammography and, increasingly, digital tomosynthesis. The NCCN Breast Cancer Screening and Diagnosis Panel concluded that the evidence supports a category 1 recommendation for screening mammography to reduce breast cancer mortality ("Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate"). 5 Combined analysis of RCTs, primarily conducted in Northern Europe, have shown a significant mortality reduction of approximately 20% among invited women aged 39 to 74 years. 1, 3 The benefit was not typically evident until 5 to 7 years after onset of screening. Too few women were aged >74 years to allow assessment. The RCTs were by invitation, not participation, and mimicked "intention to treat" and not "as treated," and hence they suffered from noncompliance and contamination. Mammography RCTs are now many decades old, with only one trial occurring in the United States that is 50 years old. Due to enormous changes in mammographic technique and changes in therapy, the application to current practice of these older studies is dated.
The recent ACS comprehensive screening review, using National Academy of Medicine methodology, emphasized a more contemporary analysis of case control and incidence-based mortality studies, which show greater benefit.
1 Mortality reductions for case-control studies by invitation was 31% (odds ratio [OR], 0.69; 95% CI, 0.57-0.83) and 48% (OR, 0.52; 95% CI, 0.42-0.65) among attenders when corrected for self-selection. Among incidence-based studies, the reduction was 38% (relative risk [RR], 0.62; 95% CI, 0.56-0.69) among attenders. Although these studies lack the scientific rigor of RCTs, they reflect more current imaging and treatment methods. Contemporary North American studies have relevance to the US population.
Coldman et al, 15 reporting on the Pan-Canadian screening experience involving 2.8 million women (aged 40-79 years), showed a 40% (95% CI, 33%-48%) mortality reduction among participating women across all age decades.
Age to Begin Screening
The NCCN Breast Cancer Screening and Diagnosis Panel affirmed age 40 years as the starting age based on mortality benefit for women aged 40 to 49 years. RCT meta-analysis showed an RR of 0.88 (CI, 0.73-1.0) for women aged 39 to 49 years. 2 Evidence for mortality reduction among women aged 40 to 49 years was judged as "high" by ACS.
1 Among the 2 RCTs specific for ages 40 to 49 years, the UK Age trial showed a 25% mortality reduction (rate ratio, 0.75; 95% CI, 0.58-0.97) after 10 years and a nonsignificant reduction (rate ratio, 0.88; 95% CI, 0.74-1.04) after 17 years. 16 The UK Age trial did not use digital mammography and limited imaging to one view, both of which are now known to decrease sensitivity. Modeling of the UK Age trial, assuming full compliance, demonstrated a 28% reduction (RR, 0.72; 95% CI, 0.65-0.75) at 13 years. 17 The older Canadian National Breast Screening Study of women aged 40 to 49 years did not show benefit, 18 but concerns have been expressed about its randomization techniques and image quality. More recent observational studies have shown mortality reduction for women aged 40 to 49 years. Hellquist et al, 19 evaluating 7.3 million women-years of screening data in Sweden, showed a 29% mortality reduction (RR, 0.71; 95% CI, 0.62-0.80) among attenders. Coldman et al 15 showed a 44% reduction (standardized mortality ratio, 0.56; 95% CI, 0.45-0.67) among Canadian women aged 40 to 49 years, a value similar to that observed for older women. The Cancer Intervention and Surveillance Modeling Network (CISNET) modeled benefit for annual screening at ages 40 to 49 years is 47 LYG/1,000 women and 1.3 deaths averted/1,000 women. 20 The same models estimate 122 LYG/1,000 women for 25 years of biennial screening at ages 50 to 74 years, which equates to 49 LYG/1,000 per decade, similar to the 47 LYG/1,000 per decade benefit from annual screening at ages 40 to 49 years. 20 Public confusion remains regarding the recent ACS and USPSTF recommendations for women aged 40 to 49 years. ACS recommends annual screening for women in their 40s; this is a "qualified recommendation" for women aged 40 to 44 years and a "strong recommendation" for those aged 45 to 49 years. 1 From a patient perspective, ACS defined "qualified recommendation" as, "The majority of individuals in this situation would want the suggested course of action, but many would not. Patient preferences and informed decision making are desirable for making decisions."
1 "Strong recommendation" was defined as, "Most individuals in this situation would want the recommended course of action and only a small proportion would not."
1 ACS demonstrated substantial disease burden for women in their 40s, showing the most person-years of life lost to breast cancer for any 5-year period occurred at diagnosis in women aged 45 to 49 years. 1 The 5-year absolute breast cancer risk from age 45 to 49 years was 0.9%, similar to the 1.1% at age 50 to 54 years. 1 The USP-STF issued a grade C recommendation for biennial screening in women aged 40 to 49 years, and recommended an individual decision, but noted, "For women in their 40s, the benefit still outweighs the harms, but to a smaller degree." 2 The NCCN recommendation is concordant with the combined strong and qualified recommendation issued by ACS for women in their 40s, but differs from that of the USPSTF.
Screening Interval
NCCN recommends annual screening, acknowledging the lack of RCT evidence on screening frequency. Given tumor growth patterns, more frequent screening would be expected to detect more clinically occult cancer. Assessment of interval cancer rates (palpable cancers occurring between screen dates) has shown higher rates when screening intervals increase. [21] [22] [23] Retrospective studies suggest smaller or earlier-stage cancers are detected with annual versus biennial screening, although this advantage may decrease as women age. 1, 24, 25 Computer models show more benefit with more frequent screening. 17, [26] [27] [28] For example, UK models for annual screening in women aged 40 to 73 years show a 36.7% mortality reduction, nearly double the 20.1% reduction for triennial screening. 27 CISNET models of screening in women aged 40 to 74 years estimate 192 LYG/1,000 women for annual screening and 152 LYG/1,000 women for biennial screening, reflecting an improvement of 26% for annual screening. 17 Compliance issues regarding annual versus biennial screening recommendations have been incompletely studied.
Age to Stop Screening
NCCN has not established an upper age for screening, but notes the decision should be based on severe comorbid conditions, which may limit life expectancy and a women's decision not to pursue treatment if diagnosed. Because RCTs show a lag in mortality benefit of 5 to 7 years, continuing screening among women with limited life expectancy does not seem warranted. The ACS has recommended 10 years of remaining life expectancy, which is the average life expectancy at age 80 years.
Adverse Effects of Mammographic Screening
All screening, including mammography, has the potential to subject women to adverse effects or risks (harms). Most women will not individually benefit from screening mammography (and most screening tests) because most will not develop breast cancer. NCCN is unaware of an accepted patient-centered metric that equates averting death from breast cancer with nonlethal risks. As such, the value assessment of risks is subjective and will vary among individuals. Restrictive screening recommendations that delay screening to age 50 years or advise less frequent intervals place a greater emphasis on the risks of screening, especially those related to false-positive results and overdiagnosis.
Frequently cited risks include recalls (or callbacks), false-positive biopsy results, and overdiagnosis. False-positives are often misunderstood, because recalls and false-positive biopsy results may be clumped together as "false-positives," although they reflect very different risks. A recall occurs when the original 2-view screening mammogram reflects a suspicious finding, which requires additional diagnostic mammograms or ultrasound to resolve. The federal Mammography Quality Standards Act considers these examinations "incomplete." 29 Most recalls will be considered negative after additional imaging. False-positive biopsy results occur when a decision to recommend a biopsy leads to a benign pathologic result. The frequency of false-positive biopsy recommendations is 7.0% to 9.4% per decade of annual screening, depending on start age. 2 Stated differently, an annually screened woman would expect to receive a false-positive biopsy recommendation averaging approximately once every 106 to 143 years of annual screening. Currently, most biopsies are performed as image-directed core needle biopsies in an outpatient setting using local anesthesia, which is the preferred biopsy method by NCCN. 5 Overall, the estimated ratio of LYG benefit to falsepositive biopsy recommendation is 1.0 LYG per benign biopsy. 30 Arguments to delay or restrict screening due to higher recall and false-positive biopsy rates in women in their 40s compared with those in their 50s have confused prevalent versus incidence screening considerations with starting age. There will be more recalls and false-positive biopsy recommendations at first (prevalent) screening, whether this occurs at age 40 or 50 years. Hubbard et al 31 showed the per decade recall rate to be the same whether annual screening began at 40 or 50 years of age (61% per decade or 6.1% per annual screening). The false-positive biopsy recommendation was higher when screening began at age 50 years (9.4% for 10 years) than at age 40 years (7.0% for 10 years). Annual screening from age 40 to 49 years results in slightly higher false-positive biopsy rates than biennial screening (7% vs 5% for 10 years, respectively). 31 A proportion of false-positive biopsies, although currently classified as benign, reveal high-risk or premalignant conditions, such as lobular carcinoma in situ or atypical ductal hyperplasia, which allows for alternative risk management decisions and may be preventive.
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Overdiagnosis
Overdiagnosis is defined as breast cancer detected by screening that would not have become clinically apparent in a woman's lifetime by usual care. The main harm of overdiagnosis relates to its associated treatment. Most commonly, overdiagnosis is attributed to competing causes of death occurring during the lead time after screen detection. Overdiagnosis is primarily a consideration for older women who face more competing causes of death. For example, Hendrick 32 calculated type 1 overdiagnosis to be <1% for premenopausal women and 22% at age 80 years. There is an extremely wide range (-5% to 75%) of estimates of overdiagnosis related to screening reflecting a myriad of varying assumptions. [1] [2] [3] [33] [34] [35] [36] [37] [38] [39] [40] [41] All measurements have limitations, and prospective prediction of an overdiagnosed cancer at an individual level is not possible. The EUROSCREEN Working Group review estimated overdiagnosis (for combined invasive cancer and ductal carcinoma in situ) at 1% to 10% in their analysis of 16 studies after appropriate adjustments were made for lead time, risk, and background trends, factors glaringly absent in some studies. 33 Overdiagnosis does not determine when to start screening or the interval at which to screen, but rather whether to screen. Neither the age at which to start screening nor the screen interval should substantially influence overdiagnosis, because these cancers would be expected to be persistent until screen-detected. 42 More fundamentally, the underlying premise of overdiagnosis is that the amount or level of diagnosis at usual clinical care is optimal or ideal and the screen level is excessive. However, the potential risk of overdiagnosis with screening must be balanced with the known harm of "overdying" without screening. Limiting the level of diagnosis to symptomatic disease is averse to many aspects of contemporary medicine, which seeks to avoid symptomatic disease by diagnosing and successfully treating presymptomatic conditions even as incidence increases. Hypertension is diagnosed and treated among asymptomatic individuals to avoid symptomatic detection at the time of a cardiovascular event, even though the incidence of screen-detected hypertension is much higher than symptomatic detection would be. Furthermore, the continuing advances in personalized treatment of newly diagnosed cancer will diminish the significance of overdiagnosis by reducing treatment morbidity.
NCCN believes the risks of screening should be balanced against the risk of not screening. The absence of mammographic screening does not equate with the absence of risk, as many assume. The net risks are the valid measure of risk. Nonscreened women frequently develop symptoms and undergo diagnostic physical examinations, mammographic imaging, and interventional biopsies, most with false-positive (benign) outcomes. Barton et al 43 showed a 23% symptomatic presentation rate among women aged 40 to 69 years during a decade of observation (32% among women aged 40-49 years), with 27% of symptomatic encounters leading to invasive procedures and an overall 6.2% positive predictive value. Importantly, there were significantly fewer symptomatic evaluations among screened women compared with nonscreened women. Symptomatic evaluations subject women to the risks of clinical encounters, anxiety, false-positive assessments, and potential for mammographic overdiagnosis.
But the greatest harm of not screening or screening less frequently is preventable death. Arleo et al, 30 using CISNET model results, showed substantially higher benefit with annual screening from age 40 to 84 years compared with biennial screening from age 50 to 74 years. A 72% improvement in LYG (189 vs 110/1,000 women) was noted, with a similar improvement in mortality reduction (39.6% vs 23.2%). To achieve these improvements, more mammograms (36,550 vs 11,066/1,000 women) and downstream testing would be performed. A total of 11.9 per 1,000 breast cancer deaths were estimated to be averted with annual screening beginning at 40 years. To put these numbers in perspective, 5.3 women need to be screened per each LYG when annual screening begins at 40 years. 30 Because the purpose of screening is to decrease breast cancer mortality and morbidity, the NCCN Guidelines for Breast Cancer Screening and Diagnosis weigh the benefits substantially higher than the risks in determining the current recommendation of annual screening beginning at age 40 years. The panel recognizes that some women will choose to screen later, less frequently, or not at all. However, women should be provided with the opportunity to elect the screening regimen that has the highest associated benefit, which remains the purpose of screening.
